Australia builds Nobel-prize science. We invest in the companies that carry it to market.
An AUD $30M early-stage ESVCLP backing Australian deep tech at its highest leverage point — from pre-seed to Series A — with an Asian corridor no other Australian fund has.
Science. Scale. Symbiosis.
Three structural advantages that compound into a fund Australia hasn't had before.
Specialists, not generalists
Sector-deep due diligence from a team that includes an FDA-approved drug inventor and operators who have built and sold real businesses across healthcare, advanced manufacturing, clean energy and AI.
Australian invention → Asian scale
A direct corridor into Greater China, Singapore and Japan — manufacturing, customers, strategic capital. The path our founders can't get from Australia-only investors.
Aligned with founders
Long-term capital, active board partnership and a GP team that has been on the founder side of the table. Every partner has personally invested in Fund II.
Why Australia, why now
Australia generates Nobel-prize-level science. The capital infrastructure to commercialise it is still being built. Right now is the entry advantage.
Strong research output, weak commercialisation infrastructure. Most Australian deep tech that scaled, scaled offshore.
Government funders (NRF, MRFF, ARC) direct capital to early-stage deep tech. Valuations sit 3–4× below Silicon Valley. The window is open and narrowing.
First major Australian deep-tech exits materialise. Valuations begin moving toward global benchmarks. Entry advantage compresses.
Four structural moats
Inside the research pipeline
- 15+ direct research-institution relationships across Australia
- 800+ projects reviewed annually — acceptance rate under 1%
- Kite Magnetics sourced from Monash pre-IP-assignment
Inventor-grade evaluation
- Partner team includes the inventor of one of only two FDA-approved small-molecule drugs originating from Australia
- Expert network drawn from Tokyo Tech, Tsinghua and other tier-1 institutions
- Independent technical validation on every investment
Two-way Asian capital network
- Long-running relationships with Chinese capital including Lilly Asia Ventures
- Manufacturing and customer access via partners in SIP, NICE and Greater Bay Area
- Exit pathways into HKEX and SSE that Australia-only investors cannot offer
Active value creation
- Active board participation and strategic coaching
- Industry partnerships brokered for every portfolio company
- AI-assisted portfolio monitoring and tiered risk response
Boson Eoarchean Fund I — a top-decile 2021 vintage.
Newton Fund II carries forward Eoarchean's team, thesis, and operating model. Eoarchean (2021 vintage) is now five years in with 92% of value unrealised under IPEV standards — substantial remaining upside, and the basis for our conviction in Newton II.
3.27×
Fund I TVPI · as of Q1 2026
Top 10% of 2021 vintage venture funds globally — a cohort defined by market turbulence and rising rates. Fund I peer median is 0.99×. 85% of 2021 vintage peers remain at zero DPI. We have already delivered liquidity events including a 2× MOIC ASX IPO in eleven months on Clarity Pharma.
| Company | Sector | MOIC | Status |
|---|---|---|---|
| Hello Clever | Fintech · AI payments | 9.5× | Active |
| Fiable | B2B SaaS · Construction | 7.0× | Active |
| Kite Magnetics | Advanced materials · Cleantech | 5.0× | Active |
| Osara Health | Digital healthcare | 3.5× | Active |
| AINC | AI for manufacturing | 3.5× | Active |
| Catalyser | B2B SaaS · CSR | 1.0× | Active |
| Storipress | SaaS · Media tech | 0× | Wound down |
| Loop+ | SaaS · Workplace | 0× | Wound down |
Pre-Seed to Series A — before growth investors price the risk out
We don't spread thin. We concentrate in sectors where Australia leads and our diligence team has genuine edge.
Investment sectors
A focused allocation across the verticals Australia leads globally — with sector specialists who can underwrite real technical risk.
Sweet spot & reserves
~20 initial positions of $500K–$1.5M each across Pre-Seed and Seed, then ~41% reserve capital (industry average 30%) for follow-on into the eight strongest names through Series A.
A tax-efficient ESVCLP, GP-aligned
A registered Australian ESVCLP (ILP2400024). 10% non-refundable tax offset and CGT exemption on eligible investments — plus flow-through taxation and an SMSF pathway.
Request the Information Memorandum
Qualifying investors can request the full Boson Newton Fund II Information Memorandum, including detailed Fund I performance, portfolio breakdowns, and fund terms.
Boson Newton Fund II is a registered Early Stage Venture Capital Limited Partnership (ESVCLP) authorised under the Venture Capital Act 2002 (Cth). Issued by Boson Health Tech VC Pty Ltd ACN 662 619 383 (CAR 74472211) of Sagestone Asset Management Pty Ltd ACN 621 697 621 (AFSL 700034). For wholesale investors only. Read the full disclaimer at /disclaimer.